Why Is Intel Struggling Against AMD?
Due to its disappointing reports, so-so management, and lack of…
Buy
54
CORBF Quote, Financials, Valuation and Earnings
Last price:
$0.95
Seasonality move
:
-4.35%
Day range:
$0.95 - $0.95
52-week range:
$0.25 - $2.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.60x
P/B ratio:
0.17x
Volume:
--
Avg. volume:
247.9K
1-year change:
-29.63%
Market cap:
$127.2M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Global Cord Blood has -- downside to fair value with a price target of -- per share.
CORBF vs. S&P 500
-
Over the past 5 trading days, Global Cord Blood has overperformed the S&P 500 by 43.62% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Global Cord Blood does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Global Cord Blood has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Global Cord Blood reported revenues of --.
Earnings Growth
-
Global Cord Blood earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Global Cord Blood reported earnings per share of --.
Enterprise value:
-919.6M
EV / Invested capital:
--
Price / LTM sales:
0.60x
EV / EBIT:
-9.70x
EV / Revenue:
-4.75x
PEG ratio (5yr expected):
0.37x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-9.70x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2021-03-31 | 2022-03-31 | |
| Income Statement | ||||||
| Revenue | $175.2M | $171.3M | $193.5M | $46.6M | $46.8M | |
| Gross Profit | $148.1M | $144.9M | $165M | $39.5M | $40.2M | |
| Operating Income | $80.2M | $80.5M | $94.8M | $22.8M | $22.4M | |
| EBITDA | $80.2M | $80.5M | $94.8M | $22.8M | $22.4M | |
| Diluted EPS | $0.56 | $0.62 | $0.64 | $0.16 | $0.14 | |
| Period Ending | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $701.2M | $766.8M | $796.9M | $956.9M | $1.1B | |
| Total Assets | $929.6M | $975.8M | $1B | $1.2B | $1.3B | |
| Current Liabilities | $74.5M | $88.7M | $80.3M | $95.2M | $101.7M | |
| Total Liabilities | $433.5M | $466M | $468.5M | $534.5M | $574M | |
| Total Equity | $496.1M | $509.9M | $546.9M | $666.7M | $768.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2007-03-31 | 2008-03-31 | 2009-03-31 | 2008-03-31 | 2009-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$441.8K | -$598.4K | -$83.6K | -$80.2K | |
| Cash From Investing | -- | $457K | $5.7M | -$161K | -- | |
| Cash From Financing | -- | $18.3K | -$5.2M | -$24.9K | $66.5K | |
| Free Cash Flow | -- | -$441.8K | -$598.4K | -$83.6K | -$80.2K | |
CORBF
Sector
Market Cap
$127.2M
$34.9M
Price % of 52-Week High
47.5%
42.85%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-29.63%
-40.42%
Beta (5-Year)
-0.640
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.76
200-day SMA
Sell
Level
$1.22
Bollinger Bands (100)
Sell
Level
0.82 - 1.22
Chaikin Money Flow
Buy
Level
22.9M
20-day SMA
Buy
Level
$0.91
Relative Strength Index (RSI14)
Buy
Level
53.27
ADX Line
Neutral
Level
17.22
Williams %R
Neutral
Level
-40
50-day SMA
Buy
Level
$0.92
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
16.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Global Cord Blood Corp provides cord blood banking services. The company provides cord blood processing and storage services for expectant parents interested in capturing the evolving medical treatments and technologies such as cord blood transplants.
Stock Forecast FAQ
In the current month, CORBF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CORBF average analyst price target in the past 3 months is --.
-
Where Will Global Cord Blood Stock Be In 1 Year?
According to analysts, the consensus estimate is that Global Cord Blood share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Global Cord Blood?
Analysts are divided on their view about Global Cord Blood share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Global Cord Blood is a Sell and believe this share price will rise from its current level to --.
-
What Is Global Cord Blood's Price Target?
The price target for Global Cord Blood over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CORBF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Global Cord Blood is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CORBF?
You can purchase shares of Global Cord Blood via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Global Cord Blood shares.
-
What Is The Global Cord Blood Share Price Today?
Global Cord Blood was last trading at $0.95 per share. This represents the most recent stock quote for Global Cord Blood. Yesterday, Global Cord Blood closed at $0.95 per share.
-
How To Buy Global Cord Blood Stock Online?
In order to purchase Global Cord Blood stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
49
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 34x
Alerts
Buy
71
PEGA alert for Apr 24
Pegasystems [PEGA] is up 28.8% over the past day.
Buy
67
SMMT alert for Apr 24
Summit Therapeutics [SMMT] is up 21.57% over the past day.
Sell
36
ENPH alert for Apr 24
Enphase Energy [ENPH] is down 15.59% over the past day.
